CA2304108A1 - Inhibition de l'apoptose au moyen d'agonistes du recepteur de la prosaposine - Google Patents

Inhibition de l'apoptose au moyen d'agonistes du recepteur de la prosaposine Download PDF

Info

Publication number
CA2304108A1
CA2304108A1 CA002304108A CA2304108A CA2304108A1 CA 2304108 A1 CA2304108 A1 CA 2304108A1 CA 002304108 A CA002304108 A CA 002304108A CA 2304108 A CA2304108 A CA 2304108A CA 2304108 A1 CA2304108 A1 CA 2304108A1
Authority
CA
Canada
Prior art keywords
seq
prosaposin
apoptosis
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002304108A
Other languages
English (en)
Inventor
John S. O'brien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2304108A1 publication Critical patent/CA2304108A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé permettant d'inhiber l'apoptose liée à la caspase, par l'administration d'agonistes du récepteur de la prosaposine. L'apoptose constitue un facteur causal majeur dans des maladies telles que la polyarthrite rhumatoïde, le syndrome du côlon irritable, l'insuffisance cardiaque globale, la sclérose en plaques, la maladie d'Alzheimer, la maladie de Parkinson, l'infarctus du myocarde et l'ischémie coronarienne.
CA002304108A 1997-09-09 1998-09-09 Inhibition de l'apoptose au moyen d'agonistes du recepteur de la prosaposine Abandoned CA2304108A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5835297P 1997-09-09 1997-09-09
US60/058,352 1997-09-09
US8812998P 1998-06-04 1998-06-04
US60/088,129 1998-06-04
PCT/US1998/019216 WO1999012559A1 (fr) 1997-09-09 1998-09-09 Inhibition de l'apoptose au moyen d'agonistes du recepteur de la prosaposine

Publications (1)

Publication Number Publication Date
CA2304108A1 true CA2304108A1 (fr) 1999-03-18

Family

ID=26737533

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002304108A Abandoned CA2304108A1 (fr) 1997-09-09 1998-09-09 Inhibition de l'apoptose au moyen d'agonistes du recepteur de la prosaposine

Country Status (5)

Country Link
EP (1) EP1011709A4 (fr)
JP (1) JP2001515866A (fr)
AU (1) AU9774698A (fr)
CA (1) CA2304108A1 (fr)
WO (1) WO1999012559A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
AU4669499A (en) * 1998-06-08 1999-12-30 Pharmacia & Upjohn Ab New therapeutic use of pkb (proteine kinase b) enhancers
US6500431B1 (en) * 1998-07-13 2002-12-31 University Of Southern California Inhibitors of angiogenesis and tumor growth
EP1112090A2 (fr) * 1998-09-09 2001-07-04 Myelos Corporation Procede pour stimuler l'activite du recepteur de la prosaposine
CA2335391A1 (fr) * 1998-10-02 2000-04-13 Kenneth Walsh Compositions akt augmentant la survie de cellules
US7368420B1 (en) 1998-10-02 2008-05-06 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Akt compositions for enhancing survival of cells
ATE281432T1 (de) 1999-03-05 2004-11-15 Univ Duke C-16 ungesätigte fp-selektive prostaglandin analoge
JP2001010972A (ja) * 1999-06-30 2001-01-16 Masahiro Sakanaka プロサポシン関連ペプチドからなる細胞保護剤
WO2001055198A2 (fr) * 2000-01-26 2001-08-02 Memorec Medical Molecular Research Cologne Stoffel Gmbh Activateur de sphingolipide specifique de la peau et de l'estomac
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
DE10037759A1 (de) * 2000-08-03 2002-07-04 Gruenenthal Gmbh Screeningverfahren
EP1673102A1 (fr) * 2003-10-17 2006-06-28 Crucell Holland B.V. Traitement et prevention d'escarres de decubitus
JP2007526022A (ja) * 2003-10-24 2007-09-13 メドトロニック・インコーポレーテッド 炎症誘発性媒介物質の産生を減弱することによって神経性障害を処置する技法
CA2692171C (fr) 2007-06-22 2019-10-22 Randolph Watnick Procedes et utilisations de prosaposine
AU2015235978B2 (en) 2014-03-26 2019-08-08 Children's Medical Center Corporation Cyclic prosaposin peptides and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) * 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides

Also Published As

Publication number Publication date
EP1011709A4 (fr) 2003-06-18
JP2001515866A (ja) 2001-09-25
AU9774698A (en) 1999-03-29
EP1011709A1 (fr) 2000-06-28
WO1999012559A1 (fr) 1999-03-18

Similar Documents

Publication Publication Date Title
CA2304108A1 (fr) Inhibition de l'apoptose au moyen d'agonistes du recepteur de la prosaposine
US7939493B2 (en) Peptide inhibitors of protein kinase C
US5696080A (en) Pharmaceutical compositions comprising neurotrophic peptides derived from prosaposin
EP0890105B1 (fr) Méthods pour le diagnostique, pour la production des médicaments et pour le criblage de substances relatives à la maladie d'Alzheimer et des peptides derivés de l'amyloid beta
EP1575477B1 (fr) LIGAND A FORTE AFFINITE POUR LE RECEPTEUR DE LA NEUROTROPHINE p75
US7157422B2 (en) Glycogen synthase kinase-3 inhibitors
JP2007314575A (ja) 治療剤としてのプロサポシンおよびサイトカイン由来ペプチド
JPH09510715A (ja) 摂食抑制ペプチド
US20140213526A1 (en) Small survival-promoting/immunomodulatory peptide for treatment of brain damage, neurodegenerative disorders, and inflammatory disorders
US5948765A (en) Inhibition of intracellular signal transduction by 14-3-3-binding peptides
US6849602B1 (en) Compositions for alleviating neuropathic pain with prosaposin receptor agonists
US20070066526A1 (en) Method for reducing risk of and extent of injury due to stroke in hypertensive subjects
KR100831633B1 (ko) Ｆｐｒ 계열 수용체 매개 신호전달에 대하여 길항작용 하는펩티드
CA2282827A1 (fr) Procedes pour soulager les douleurs neuropathiques
JP4094814B2 (ja) 血管新生抑制剤
US20020132759A1 (en) Remedies for diseases caused by insulin resistance
JP2008508363A (ja) δプロテインキナーゼＣの調節のためのペプチド配列
HUE024953T2 (en) Peptide inhibitors to mediate stress responses
CA2284105A1 (fr) Peptides neurotrophiques de synthese derives de la saposine c
WO1998042746A9 (fr) Peptides neurotrophiques de synthese derives de la saposine c
WO2000047218A1 (fr) Regulation de la degenerescence des photorecepteurs
TW202607013A (zh) 一種包含ｐｓｄ－９５多肽抑制劑的醫藥組成物及其製備方法
AU2002300005B2 (en) Method of alleviating neuropathic pain
AU4267297A (en) Method of alleviating neuropathic pain
MXPA01001966A (en) Cyclic prosaposin-derived peptides and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued